These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27170937)

  • 21. Pharmacotherapy for onychomycosis: new and emerging treatments.
    Lipner SR
    Expert Opin Pharmacother; 2019 Apr; 20(6):725-735. PubMed ID: 30689469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of Onychomycosis in Canada in 2014.
    Gupta AK; Paquet M
    J Cutan Med Surg; 2015; 19(3):260-73. PubMed ID: 25775640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model.
    Ghannoum MA; Long L; Pfister WR
    Mycoses; 2009 Jan; 52(1):35-43. PubMed ID: 18498299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
    Schaller M; Sigurgeirsson B; Sarkany M
    Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis.
    Pollak RA
    J Am Podiatr Med Assoc; 2014 Nov; 104(6):568-73. PubMed ID: 25514267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.
    Jaiswal A; Sharma RP; Garg AP
    Indian J Dermatol Venereol Leprol; 2007; 73(6):393-6. PubMed ID: 18032857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.
    Baran R; Sigurgeirsson B; de Berker D; Kaufmann R; Lecha M; Faergemann J; Kerrouche N; Sidou F
    Br J Dermatol; 2007 Jul; 157(1):149-57. PubMed ID: 17553051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis.
    Gupta AK
    J Am Podiatr Med Assoc; 2002 May; 92(5):272-86. PubMed ID: 12015408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis.
    Matsuda Y; Sugiura K; Hashimoto T; Ueda A; Konno Y; Tatsumi Y
    PLoS One; 2016; 11(7):e0159661. PubMed ID: 27441843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topical therapy for toenail onychomycosis: an evidence-based review.
    Gupta AK; Daigle D; Foley KA
    Am J Clin Dermatol; 2014 Dec; 15(6):489-502. PubMed ID: 25257931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
    Van Doorslaer EK; Tormans G; Gupta AK; Van Rossem K; Eggleston A; Dubois DJ; De Doncker P; Haneke E
    Dermatology; 1996; 193(3):239-44. PubMed ID: 8944348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region.
    Baran R; Feuilhade M; Combernale P; Datry A; Goettmann S; Pietrini P; Viguie C; Badillet G; Larnier C; Czernielewski J
    Br J Dermatol; 2000 Jun; 142(6):1177-83. PubMed ID: 10848743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
    Avner S; Nir N; Henri T
    J Dermatolog Treat; 2005; 16(5-6):327-30. PubMed ID: 16428154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efinaconazole and Tavaborole.
    Poulakos M; Grace Y; Machin JD; Dorval E
    J Pharm Pract; 2017 Apr; 30(2):245-255. PubMed ID: 26873506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Onychomycosis in the elderly.
    Gupta AK
    Drugs Aging; 2000 Jun; 16(6):397-407. PubMed ID: 10939306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis.
    Tabara K; Szewczyk AE; Bienias W; Wojciechowska A; Pastuszka M; Oszukowska M; Kaszuba A
    Postepy Dermatol Alergol; 2015 Feb; 32(1):40-5. PubMed ID: 25821426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Randomized, Double-blind Study of Amorolfine 5% Nail Lacquer with Oral Fluconazole Compared with Oral Fluconazole Alone in the Treatment of Fingernail Onychomycosis.
    Chandra S; Sancheti K; Podder I; Das A; Sarkar TK; Chowdhury M; Sil A; Bhattacharya S; Das NK
    Indian J Dermatol; 2019; 64(4):253-260. PubMed ID: 31516132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer: A Review of Its Use in Onychomycosis.
    Piraccini BM; Iorizzo M; Lencastre A; Nenoff P; Rigopoulos D
    Dermatol Ther (Heidelb); 2020 Oct; 10(5):917-929. PubMed ID: 32705532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.
    Brenner MA; Harkless LB; Mendicino RW; Page JC
    J Am Podiatr Med Assoc; 2007; 97(3):195-202. PubMed ID: 17507527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study.
    Gupta AK;
    J Drugs Dermatol; 2005; 4(4):481-5. PubMed ID: 16004022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.